Literature DB >> 10643932

Treatment of refractory complex-partial status epilepticus with propofol: case report.

M Begemann1, A J Rowan, S Tuhrim.   

Abstract

PURPOSE: We report a case of a 65-year-old woman who had a subarachnoid and intraventricular hemorrhage secondary to rupture of an anterior communicating artery aneurysm and developed nonconvulsive status epilepticus of the complex-partial type, refractory to phenytoin (PHT), phenobarbital (PB), valproate (VPA), and lorazepam (LZP).
METHODS: Three weeks after diagnosis of nonconvulsive status epilepticus, general anesthesia was induced with propofol and titrated to burst suppression on the electroencephalogram (EEG).
RESULTS: During propofol infusion, the serum VPA level declined markedly, and despite >3 g daily doses, did not return to the therapeutic range, until several days after propofol was discontinued. Continuous propofol infusion was stopped after 7 days, and the patient recovered consciousness. Despite further complications, she gradually regained normal function and was discharged home 4 months after surgery.
CONCLUSIONS: This is the first case of nonconvulsive status epilepticus successfully treated with propofol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10643932     DOI: 10.1111/j.1528-1157.2000.tb01513.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Diagnosis and Treatment of Nonconvulsive Status Epilepticus in an Intensive Care Unit Setting.

Authors:  Stephan J. Rüegg; Marc A. Dichter
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

Review 2.  [Refractory status epilepticus: diagnosis, therapy, course, and prognosis].

Authors:  F Bösebeck; G Möddel; K Anneken; M Fischera; S Evers; E B Ringelstein; C Kellinghaus
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

3.  Animal models for the development of new neuropharmacological therapeutics in the status epilepticus.

Authors:  Ed Martín; Ma Pozo
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 4.  Clinical review: status epilepticus.

Authors:  Sarice Bassin; Teresa L Smith; Thomas P Bleck
Journal:  Crit Care       Date:  2002-03-15       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.